Abstract
When treating diabetic foot ulcers it is important to be aware of the natural history of the diabetic foot, which can be divided into five stages: stage 1, a normal foot; stage 2, a high risk foot; stage 3, an ulcerated foot; stage 4, an infected foot; and stage 5, a necrotic foot. This covers the entire spectrum of foot disease but emphasises the development of the foot ulcer as a pivotal event in stage 3, which demands urgent and aggressive management. Diabetic foot care in all stages needs multidisciplinary management to control mechanical, wound, microbiological, vascular, metabolic and educational aspects. Achieving good metabolic control of blood glucose, lipids and blood pressure is important in each stage, as is education to teach proper foot care appropriate for each stage.
Ideally, it is important to prevent the development of ulcers in stages 1 and 2. In stage 1, the normal foot, it is important to encourage the use of suitable footwear, and to educate the patient to promote healthy foot care and footwear habits. In stage 2, the foot has developed one or more of the following risk factors for ulceration: neuropathy, ischaemia, deformity, swelling and callus. The majority of deformities can be accommodated in special footwear and as callus is an important precursor of ulceration it should be treated aggressively, especially in the neuropathic foot. In stage 3, ulcers can be divided into two distinct entities: those in the neuropathic foot and those in the neuroischaemic foot. In the neuropathic foot, ulcers commonly develop on the plantar surface of the foot and the toes, and are associated with neglected callus and high plantar pressures. In the neuroischaemic foot, ulcers are commonly seen around the edges of the foot, including the apices of the toes and back of the heel, and are associated with trauma or wearing unsuitable shoes. Ulcers in stage 3 need relief of pressure (mechanical control), sharp debridement and dressings (wound control), and neuroischaemic foot ulcers may need vascular intervention (vascular control). In stage 4, microbiological control is crucial and severe infections need intravenous antibacterial therapy, and urgent assessment of the need for surgical drainage and debridement. Without urgent treatment, severe infections will progress to necrosis. In stage 5, necrosis can be divided into wet and dry necrosis. Wet necrosis in neuropathic feet requires intravenous antibacterials and surgical debridement, and wet necrosis in neuroischaemic feet also needs vascular reconstruction. Aggressive management of diabetic foot ulceration will reduce the number of feet proceeding to infection and necrosis, and thus reduce the number of major amputations in diabetic patients.
Similar content being viewed by others
Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
References
Reiber GE. Epidemiology of foot ulcers and amputations in the diabetic foot. In: Bowker JH, Pfeifer MA, editors. Levin and O’Neal’s the diabetic foot. 6th ed. St Louis: Mosby, 2001: 13–32
Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation: basis for prevention. Diabetes Care 1990 May; 13(5): 513–21s
Bakker K, Foster AVM, van Houtum WH, et al., editors. Diabetes and foot care: time to act. Brussels: International Diabetes Federation/International Working Group of the Diabetic Foot, 2005
Driver VR, Madsen J, Goodman RA. Reducing amputation rates in patients with diabetes at a military medical center: the limb preservation service model. Diabetes Care 2005 Feb; 28(2): 248–53
Edmonds M, Foster AVM. Reduction of major amputations in the diabetic ischemic foot: a strategy to ‘take control’ with conservative care as well as revascularisation. Vasa 2001; 58 Suppl.: 6–14
Rith-Najarian S, Branchaud C, Beaulieu O, et al. Reducing lower-extremity amputations due to diabetes. J Fam Pract 1998; 47: 127–32
Rith-Najarian S, Gohdes D. Preventing amputations among patients with diabetes on dialysis. Diabetes Care 2000; 23: 1445–6
van Houtum WH, Rauwerda JA, Ruwaard D, et al. Reduction in diabetes-related lower-extremity amputations in The Netherlands: 1991–2000. Diabetes Care 2004; 27: 1042–6
Mason J, O’Keeffe C, Mclntosh A, et al. A systematic review of foot ulcer in patients with Type 2 diabetes: I. prevention. Diabet Med 1999; 16: 801–12
Mason JM, O’Keefe C, Mclntosh A, et al. A systematic review of foot ulcer in patients with Type 2 diabetes: II. treatment. Diabet Med 1999; 16: 889–909
Hunt D, Gerstein H. Foot ulcers in diabetes. Clin Evid 2001; 5: 397–402
Eldor R, Raz I, Ben Yehuda A, et al. New and experimental approaches to treatment of diabetic foot ulcers: a comprehensive review of emerging treatment strategies. Diabet Med 2004 Nov; 21(11): 1161–73
Wraight PR, Lawrence SM, Campbell DA, et al. Creation of a multidisciplinary, evidence based, clinical guideline for the assessment, investigation and management of acute diabetes related foot complications. Diabet Med 2005 Feb; 22(2): 127–36
Hutchinson A, Mclntosh A, Feder G, et al. Clinical guidelines and evidence review for type 2 diabetes: prevention and management of foot problems. London: Royal College of General Practitioners, 2000 Apr
Pinzur MS, Slovenkai MP, Trepman E. Guidelines for diabetic foot care. Foot Ankle Int 1999; 20: 695–702
Frykberg RG, Armstrong DG, Giurini J, et al. Diabetic foot disorders: a clinical practice guideline. J Foot Ankle Surg 2000; 39 (5 Suppl.): S1–60
International Consensus on the Diabetic Foot 1999 by The International Working Group on the Diabetic Foot [online]. Available from URL: http://www.diabetic-foot-consensus.com/ [Accessed 2006 8 May]
The International Working Group on the Diabetic Foot. Practical guidelines on the management and the prevention of the diabetic foot [online]. Available from URL: http://www.diabetic-foot-consensus.com/concensus/guide-linesindex.htm [Accessed 2006 8 May]
Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis; Epub 2004 Sep 1039(7): 885–910
Reiber GE, Raugi GJ. Preventing foot ulcers and amputations in diabetes. Lancet 2005; 366(9498): 1676–7
Edmonds M, Foster AVM, Sanders LJ. A practical manual of diabetic foot care. Oxford: Blackwell Science, 2004
Rith-Najarian SJ, Stolusky T, Godhes DM. Identifying diabetic patients at risk for lower extremity amputation in a primary healthcare setting. Diabetes Care 1992; 15: 1386–9
Abbott CA, Vileikyte L, Williamson S, et al. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care 1998 Jul; 21(7): 1071–5
Miranda-Palma B, Sosenko JM, Bowker JH, et al. A comparison of the monofilament with other testing modalities for foot ulcer susceptibility. Diabetes Res Clin Pract 2005 Oct; 70(1): 8–12
McGee SR, Boyko EJ. Physical examination and chronic lower-extremity ischemia: a critical review. Arch Intern Med 1998 Jun 22; 158(12): 1357–64
American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care 2003 Dec; 26(12): 3333–41
Faglia E, Caravaggi C, Marchetti R, et al. SCAR (Screening for ARteriopathy) Study Group. Screening for peripheral arterial disease by means of the ankle-brachial index in newly diagnosed Type 2 diabetic patients. Diabet Med 2005 Oct; 22(10): 1310–4
Sanders LJ, Frykberg RG. Charcot neuroarthropathy of the foot. In: Bowker JH, Pfeifer MA, editors. Levin and O’Neal’s the diabetic foot. 6th ed. St Louis: Mosby, 2000: 467–482
Jude EB, Selby PL, Burgess J, et al. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia 2001 Nov; 44(11): 2032–7
McCabe CJ, Stevenson RC, Dolan AM. Evaluation of a diabetic foot screening and protection programme. Diabet Med 1998; 15: 80–4
McGill M, Molyneaux L, Yue DK. Which diabetic patients should receive podiatry care?. An objective analysis. Intern Med J 2005 Aug; 35(8): 451–6
Valk GD, Kriegsman DMW, Assendelft WJJ. Patient education for preventing diabetic foot ulceration (Cochrane Review). Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 3. Oxford: Update Software, 2003
Malone JM, Snyder M, Anderson G, et al. Prevention of amputation by diabetic education. Am J Surg 1989; 158: 520–4
Colagiuri S, Marsden L, Naidu V, et al. The use of orthotic devices to correct plantar callus in people with diabetes. Diabetes Res Clin Prac 1995; 28: 29–34
Maciejewski ML, Reiber GL, Smith DG, et al. Effectiveness of diabetic therapeutic footwear in preventing reulceration. Diabetes Care 2004; 27: 1774–82
Uccioli L, Aldeghi A, Faglia E, et al. Manufactured shoes in the prevention of diabetic foot ulcers. Diabetes Care 1995; 18: 1376–8
Reiber GE, Smith DG, Wallace C, et al. Effect of therapeutic footwear on foot reulceration in patients with diabetes: a randomized controlled trial. JAMA 2002; 287(19): 2552–8
Boulton AJ, Jude EB. Therapeutic footwear in diabetes: the good, the bad, and the ugly? Diabetes Care 2004 Jul; 27(7): 1832–3
Peters EJG, Lavery LA. Effectiveness of the diabetic foot risk classification system of the International working group on the diabetic foot. Diabetes Care 2001; 24: 1442–7
Boulton AJ. The diabetic foot: from art to science: the 18th Camillo Golgi lecture. Diabetologia; Epub 2004 Jul 2847(8): 1343–53
Nabuurs-Franssen MH, Sleegers R, Huijberts MS, et al. Total contact casting of the diabetic foot in daily practice: a prospective follow-up study. Diabetes Care 2005 Feb; 28(2): 243–7
Nabuurs-Franssen MH, Huijberts MS, Sleegers R, et al. Casting of recurrent diabetic foot ulcers: effective and safe? Diabetes Care 2005 Jun; 28(6): 1493–4
Caravaggi C, Faglia E, De Giglio R, et al. Effectiveness and safety of a non-removable fibreglass oo-bearing cast versus a therapeutic shoe in the treatment of neuropathic foot ulcers: a randomised study. Diabetes Care 2000; 23: 1746–51
Katz IA, Harlan A, Miranda-Palma B, et al. A randomized trial of two irremovable off-loading devices in the management of plantar neuropathic diabetic foot ulcers. Diabetes Care 2005; 28(3): 555–9
Armstrong DG, Nguyen HC, Lavery LA, et al. Off loading the diabetic foot wound. Diabetes Care 2001; 24: 1019–22
Edmonds ME, Foster AVM. Managing the diabetic foot. Oxford: Blackwell Science, 2005
Steed DL. Foundations of good ulcer care. Am J Surg 1998; 176 Suppl 2a: 20S–5S
Wolff H, Hansson C. Larval therapy: an effective method of ulcer debridement. Clin Exp Dermatol 2003 Mar; 28(2): 134–7
Rayman A, Stansfield G, Woollard T, et al. Use of larvae in the treatment of the diabetic necrotic foot. Diabetic Foot 1998; 1: 7–13
Armstrong DG, Salas P, Short B, et al. Maggot therapy in “lower-extremity hospice” wound care: fewer amputations and more antibiotic-free days. J Am Podiatr Med Assoc 2005 May–Jun; 95(3): 254–7
Falanga V. Wound healing and its impairment in the diabetic foot. Lancet 2005 Nov 12; 366(9498): 1736–43
Hilton JR, Williams DT, Beuker B, et al. Wound dressings in diabetic foot disease. Clin Infect Dis 2004; 39 Suppl. 2: S100–3
Falanga V, Sabolinski ML. Prognostic factors for healing of venous and diabetic ulcers. Wounds 2000; 12: 42A-6A
Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet derived growth factor: BB (Becaplermin) in patients with non healing diabetic ulcers. A phase III, randomized, placebo-controlled, double-blind study. Diabetes Care 1998; 21: 822–7
Naughton G, Mansbridge J, Gentzkow G. A metabolically active human dermal replacement for the treatment of diabetic foot ulcers. Artif Organs 1997; 21: 1203–10
Marston WA, Hanft J, Norwood P, et al. Dermagraft Diabetic Foot Ulcer Study Group. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care 2003 Jun; 26(6): 1701–5
Veves A, Falanga V, Armstrong DG, et al. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 2001 Feb; 24(2): 290–5
Edmonds M, Bates M, Doxford M, et al. New treatments in ulcer healing and wound infection. Diabetes/Metabolism Research and Reviews. Vol 2000; 16 Suppl. 1: S51–4
Badiavas EV, Falanga V. Treatment of chronic wounds with bone marrow-derived cells. Arch Dermatol 2003; 139: 510–6
Veves A, Sheehan P, Pham HT. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg 2002 Jul; 137(7): 822–7
Armstrong DG, Lavery LA, Diabetic Foot Study Consortium. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial. Lancet 2005 Nov 12; 366(9498): 1704–10
Faglia E, Favales F, Aldeghi A, et al. Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer: a randomized study. Diabetes Care 1996 Dec; 19(12): 1338–43
Wunderlich RP, Peters EJ, Lavery LA. Systemic hyperbaric oxygen therapy: lower-extremity wound healing and the diabetic foot. Diabetes Care Oct 2000; 23(10): 1551–5
Edmonds M, Foster A. The use of antibiotics in the diabetic foot. Am J Surg 2004 May; 187(5A): 25S–8S
Cavanagh PR, Lipsky BA, Bradbury AW, et al. Treatment for diabetic foot ulcers. Lancet 2005 Nov 12; 366(9498): 1725–35
Rayman G, Rayman A, Baker NR, et al. Sustained silver-releasing dressing in the treatment of diabetic foot ulcers. Br J Nurs 2005 Jan 27–Feb 9; 14(2): 109–14
Chantelau E, Tanudjaja T, Altenhofer F, et al. Antibiotic treatment for uncomplicated neuropathic forefoot ulcers in diabetes: a controlled trial. Diabet Med 1996; 13: 156–9
Edmonds ME, Walters H. Angioplasty and the diabetic foot. Vasc Med Rev 1995; 6: 205–14
Sigala F, Menenakos CH, Sigalas P, et al. Transluminal angioplasty of isolated crural arterial lesions in diabetics with critical limb ischemia. Vasa 2005 Aug; 34(3): 186–91
Eneroth M, Apelqvist J, Stenstrom A. Clinical characteristics and outcome in 223 diabetic patients with deep foot infections. Foot Ankle Int 1997; 18: 716–22
Morrison WB, Schweitzer ME, Batte WG, et al. Osteomyelitis of the foot: relative importance of primary and secondary MR imaging signs. Radiology 1998 Jun; 207(3): 625–32
Grayson ML, Gibbons GW, Balogh K, et al. Probing to bone in infected pedal ulcers: a clinical sign of underlying osteomyelitis in diabetic patients. JAMA 1995; 273: 721–3
Tentolouris N, Petrikkos G, Vallianou N, et al. Prevalence of methicillin-resistant Staphylococcus aureus in infected and uninfected diabetic foot ulcers. N Clin Microbiol Infect 2006 Feb; 12(2): 186–9
Pellizzer G, Strazzabosco M, Presi S, et al. Deep tissue biopsy vs superficial swab culture monitoring in the microbiological assessment of limb-threatening diabetic foot infection. Diabet Med 2001; 18: 822–7
Slater RA, Lazarovitch T, Boldur I, et al. Swab cultures accurately identify bacterial pathogens in diabetic foot wounds not involving bone. Diabet Med 2004 Jul; 21(7): 705–9
Senneville E, Melliez H, Beltrand E, et al. Culture of percutaneous bone biopsy specimens for diagnosis of diabetic foot osteomyelitis: concordance with ulcer swab cultures. Clin Infect Dis; Epub 2005 Nov 2142(1): 57–62
Lipsky BA, Armstrong DG, Citron DM, et al. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet 2005 Nov 12; 366(9498): 1695–703
Harkless L, Boghossian J, Pollak R, et al. An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers. Surg Infect (Larchmt) 2005 Spring; 6(1): 27–40
Clay PG, Graham MR, Lindsey CC, et al. Clinical efficacy, tolerability, and cost savings associated with the use of open-label metronidazole plus ceftriaxone once daily compared with every 6 hours as empiric treatment for diabetic lower-extremity infections in older males. Am J Geriatr Pharmacother 2004 Sep; 2(3): 181–9
Venkatesan P, Lawn S, Macfarlane RM, et al. Conservative management of osteomyelitis in the feet of diabetic patients. Diabet Med 1997; 14: 487–90
Lioupis C. The role of distal arterial reconstruction in patients with diabetic foot ischemia. Int J Low Extrem Wounds 2005 Mar; 4(1): 45–9
McArthur CS, Sheahan MG, Pomposelli FB, et al. Infrainguinal revascularization after renal transplantation. J Vasc Surg 2003; 37(6): 1181–5
Ramdev P, Rayan SS, Sheahan M, et al. A decade experience with infrainguinal revascularization in a dialysis-dependent patient population. J Vasc Surg 2002; 36(5): 969–74
Acknowledgements
The author received no funding in the preparation of this manuscript. Dr Edmonds is a member of the Scientific Advisory Boards of KCI and Ark Therapeutics.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Edmonds, M. Diabetic Foot Ulcers. Drugs 66, 913–929 (2006). https://doi.org/10.2165/00003495-200666070-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-200666070-00003